Partial epigenetic reprogramming uses short pulses of three Yamanaka factors (OSK, without c-Myc) to reset epigenetic age markers while keeping cell identity. The evidence is preclinical: mouse studies show restored function and lifespan effects, and a primate model showed restored methylation patterns. The first human trial, Life Biosciences' ER-100 for optic neuropathies, dosed its first patient in June 2026. It is a small open-label safety study (n=18) with initial results expected in late 2026.
Summary drafted from this entry’s sources; editorial review pending.
01Key questions
Has epigenetic reprogramming been tested in humans?
Yes, barely. Life Biosciences' ER-100 is the first partial-reprogramming therapy in a human trial: FDA cleared the IND in January 2026 and the first patient was dosed June 9, 2026. The Phase 1 study (NCT07290244) is an open-label, non-randomized safety study of 18 participants with glaucoma or NAION.1
Does epigenetic reprogramming reverse aging?
In animals, partly. Mouse studies from the Sinclair and Belmonte groups show restored tissue function and lifespan or healthspan extension with intermittent OSK, and a non-human primate NAION model showed restored methylation patterns. Whether that translates to humans is what the ER-100 trial is starting to test.1
Is reprogramming safe? What about cancer risk?
The design stacks four mitigations: no c-Myc (the oncogenic fourth factor), transient expression switched on by doxycycline, localized intravitreal delivery to one eye, and a kill switch. Theoretical risks remain, including loss of cell identity with sustained expression and immune response to the AAV vector. Human safety data do not exist yet.1
What would change this rating?
The ER-100 readouts: initial OAG safety data expected Q4 2026, full Phase 1 safety profile by mid-2027. Clean safety would validate reprogramming as a druggable modality and likely accelerate Altos Labs' expected IND filing; problems would confine the approach to localized delivery.1
02Overview
Partial epigenetic reprogramming (PER) uses controlled expression of Yamanaka factors (primarily OSK: OCT4, SOX2, KLF4) to reset epigenetic age markers without full dedifferentiation to pluripotency. Unlike full reprogramming (which uses OSKM including c-Myc and carries teratoma risk), PER aims to restore cells to a more youthful functional state while preserving cell identity.
Landmark event: Life Biosciences received FDA IND clearance for ER-100 on January 28, 2026 — the first-ever cellular rejuvenation therapy using partial epigenetic reprogramming to reach human clinical trials. First patient dosed June 9, 2026 in Phase 1 for optic neuropathies.
03Mechanism of Action
ER-100 and the broader PER platform work by: 1. Delivering three transcription factors (OCT4, SOX2, KLF4) via an engineered adeno-associated virus (AAV) vector. 2. The factors reset epigenetic patterns (DNA methylation, chromatin state) associated with healthy cellular function — restoring cells to more youthful gene-expression profiles. 3. Does NOT alter existing genes — modifies the epigenome only (biochemical markers that regulate gene expression without changing the underlying DNA sequence). 4. Critical safety design: c-Myc is excluded (the 4th Yamanaka factor), avoiding the primary oncogenicity risk of full reprogramming.
04Human Evidence (First-in-Human Clinical Trial)
ER-100 Phase 1 — Life Biosciences (NCT07290244)
| Parameter | Detail |
|---|---|
| Sponsor | Life Biosciences, Inc. |
| Trial ID | NCT07290244 (Other: LB100-001) |
| Status | Recruiting (Phase 1, first-in-human) |
| IND Clearance | January 28, 2026 |
| Study Start (Actual) | March 2, 2026 |
| First Patient Dosed | June 9, 2026 |
| Primary Completion (Est.) | May 2027 |
| Study Completion (Est.) | March 2032 |
| Enrollment | 18 participants |
| Last Updated | May 19, 2026 |
Swipe table →
Official Title: "A Phase 1 Single Dose Study to Evaluate the Safety and Tolerability of ER-100 in Optic Neuropathies [Open Angle Glaucoma (OAG) and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)]"
Study Design — Sequential Cohort
Non-randomized, open-label, sequential assignment.
Cohort 1 — OAG Dose Escalation (12 participants): - Low dose: 2 × 10^11 vg/eye - High dose: 6 × 10^11 vg/eye - Each dose begins with a "sentinel" participant, monitored 28 days before enrolling 2 more.
Cohort 2 — NAION Dose Expansion (6 participants): - Dose selected based on OAG safety data. - Initial enrollment of 3; expansion to 6 after DSMB review.
Intervention Details
- Delivery: Single-dose intravitreal injection to one eye (localized ocular delivery avoids systemic exposure).
- Activation: Systemic doxycycline for 8 weeks (56 days) activates the OSK expression (doxycycline-inducible kill switch / regulatory cassette).
- 5-year long-term follow-up for health and vision outcomes.
- 15 clinic visits total (10 in first 6 months, then annual through Year 5).
Primary Endpoints
- Treatment-Emergent Adverse Events (TEAEs) during/post-doxycycline
- Dose-Limiting Toxicities (DLTs) during/post-doxycycline
- Laboratory safety: Liver function tests (ALT, AST, ALP, GGT, LDH)
- Secondary: Visual function assessments
Key Eligibility Criteria
- Age: 40–85 years; OAG with moderate-to-advanced visual field loss (MD -6 to -20 dB) or NAION with sudden vision loss within 14 days.
- Exclusions: Previous AAV gene therapy, cancer within 5 years, immunocompromised, tetracycline allergy, poorly controlled diabetes (A1c >7), significant cataracts/macular/corneal disease.
Data Readout Timeline
- Q4 2026: Initial safety/tolerability data from OAG sentinel + low-dose cohort expected.
- Q2 2027: Primary completion (full safety profile).
- 2032: Long-term (5-year) follow-up completion.
05Corporate & Funding Intelligence
Life Biosciences
- $80M Series D (April 2026) secured to fund first-in-human trial and platform expansion.
- CMO: Sharon Rosenzweig-Lipson, PhD (Chief Scientific Officer) — led translational research and FDA engagement.
- Platform: Epigenetic Restoration (ER) platform; ER-100 is first clinical candidate.
- Pipeline: ER-300 (MASH/hepatic indications — preclinical); ER-100 (ophthalmology — Phase 1).
- Preclinical ARDD 2025 data: ER-100 restored methylation patterns in non-human primate (NHP) NAION model; ER-300 improved MASH biomarkers in mice.
Altos Labs
- $3B funded at launch (January 2022) — largest longevity-focused biotech launch in history.
- Focus: in vivo partial reprogramming for kidney, heart, liver, brain rejuvenation.
- Belmonte group (Izpisua Belmonte) demonstrated lifespan/healthspan extension in mice; recent data on intermittent OSK activation.
- CMO appointment (2025): Joan Mannick, MD — signaling clinical trial preparation. Mannick has extensive experience in translational geroscience (prior roles at resTORbio, Tornado Therapeutics).
- No human trials announced as of July 2026. Estimated 12–24 months behind Life Bio on IND timeline.
YouthBio Sciences
- Targeting Alzheimer's disease via reprogramming approaches (preclinical stage reported).
Academic Foundations
- Stanford, MIT, Salk Institute (Belmonte): Foundational mouse studies demonstrating reversal of age-associated hallmarks (epigenetic noise reduction, improved tissue regeneration) via transient OSK expression.
- David Sinclair (Harvard): Early PER patent estate and publication record underlying Life Bio's approach.
06Preclinical / Animal Evidence
| Model | Intervention | Finding | Source |
|---|---|---|---|
| NHP (non-human primate) — NAION | ER-100 (OSK via AAV) | Restored methylation patterns; improved retinal ganglion cell function | ARDD 2025 (Life Bio) |
| Mouse — MASH/hepatic | ER-300 | Improved MASH biomarkers | ARDD 2025 (Life Bio) |
| Mouse — optic nerve injury | OSK (AAV) | Restored visual function; reversed axonal injury epigenetic signature | Sinclair lab (foundational) |
| Mouse — lifespan/healthspan | Intermittent OSK | Lifespan/healthspan extension without teratoma formation | Belmonte group |
Swipe table →
Translational note: FDA clearance for ER-100 was supported substantially by the NHP data — a key credibility milestone, as primate data is far closer to human biology than rodent studies alone. The localized ocular delivery strategy (vs systemic) was also critical for FDA comfort with the first-in-class approach.
07Translational Gaps & Regulatory Intelligence
Safety Profile
- Oncogenicity risk mitigated by: (1) partial reprogramming — no c-Myc; (2) transient expression via doxycycline control; (3) localized delivery to isolated organ (eye); (4) doxycycline-inducible kill switch.
- Human safety data pending (first patient dosed June 2026; no readout yet).
- Primary theoretical risks: Loss of cell identity if expression is sustained too long; immune response to AAV vector; off-target epigenetic effects.
Regulatory Pathway
- Traditional Phase 1 for rare/serious indications (NAION has no approved treatments; OAG is common but progressive).
- Potential for accelerated approval or RMAT (Regenerative Medicine Advanced Therapy) designation in ophthalmology, particularly for NAION (orphan indication).
- FDA demonstrated willingness to engage with reprogramming-based therapy — a positive regulatory signal for the broader field, contingent on clean ER-100 safety data.
Competitive Map 2026–2027
| Company | Lead Asset | Stage | Indication | Key Inflection |
|---|---|---|---|---|
| Life Biosciences | ER-100 | Phase 1 (recruiting) | OAG, NAION | Q4 2026 safety readout |
| Altos Labs | Undisclosed | Preclinical (IND-enabling) | Multi-organ rejuvenation | IND filing est. 2027–2028 |
| YouthBio | Undisclosed | Preclinical | Alzheimer's | Pre-IND |
| Academic (Salk/MIT) | Research tools | Basic research | Various | Publication-driven |
Swipe table →
Key Inflection Points
- Q4 2026: Life Bio ER-100 initial safety data (OAG sentinel + low-dose).
- Q2 2027: ER-100 primary completion (full Phase 1 safety profile).
- 2027–2028: Altos Labs IND filing expected.
- 2028+: Platform licensing / M&A activity likely post-Phase 1 readout, contingent on safety validation.
08Strategic Implications
- If ER-100 safety data is clean (Q4 2026): Validates PER as a druggable modality; triggers massive capital inflow to Altos Labs and emerging PER startups; enables systemic-delivery IND filings.
- If safety signals are concerning: PER remains confined to localized delivery (eye, skin) for the foreseeable future; systemic rejuvenation timeline extends 3–5 years.
- Platform thesis: PER is potentially disease-agnostic — if the epigenetic aging mechanism is causal (not just correlative), successful proof-of-concept in one indication unlocks a vast pipeline across ophthalmology, neurology, cardiology, and hepatology.
- Differentiator from senolytics: Senolytics clear damaged cells; PER restores function in viable-but-aged cells. Complementary, not competitive — combined protocols are theoretically attractive (senolytics first, then PER for remaining cells).
09Connections
10Sources
- ClinicalTrials.gov NCT07290244 — ER-100 Phase 1 (last updated 2026-05-19). Study pageNCT07290244
11Entry history
Latest content update.
Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.